Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
All content for Translational Health Sciences is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
Health Technology Assessment (HTA) in Resource-Constrained Settings: A Case Study of Ghana
Translational Health Sciences
41 minutes
1 year ago
Health Technology Assessment (HTA) in Resource-Constrained Settings: A Case Study of Ghana
Dr Brian Adu Asare discusses Health Technology Assessment (HTA) using Ghana as a case study. HTA is pivotal in informing healthcare decision-making. It is a tool which helps in ensuring effective resource allocation and optimizing health outcomes. In resource-constrained settings, such as Ghana, the institutionalization, conduct, and uptake of HTA seeks to contribute to maximizing outcomes with limited resources. In Ghana, HTA's institutionalization has been marked by the establishment governance structures, strategies, and processes as well as the integration of HTA principles into health policies. However, the process has faced challenges, including limited expertise and financial constraints. Capacity-building initiatives, such as training programs and international collaborations, have been instrumental in addressing these barriers.
Dr Brian Adu Asare is the Head of Health Technology Assessments (HTA) in Ghana and a Senior Technical Officer at the Pharmacy Directorate of the Ghana Ministry of Health. He also heads the National Drug Information, Research and Monitoring and Evaluation Unit of the Ministry of Health under the Pharmacy Directorate. He joined mainstream health policy in 2008 at the Ghana National Drugs Programme, and currently advices on technical issues in relation to pharmaceuticals in the Ghana Ministry of Health.
He has led and contributed to several technical initiatives in:
* Institutionalization and operationalization of Health Technology Assessment (HTA) in Ghana
* Evidence-based medicine (EBM)
* Pricing systems, Health systems strengthening, Antimicrobial resistance (AMR) and health information systems
* Formulation and review of National Medicines Policy
* Development and review of Standard Treatment Guidelines (STG) and Essential Medicines Lists (EML) including COVID-19 treatment guidelines for Ghana.
He currently serves on the:
* National Medicines Selection Committee
* National Medicines Price Committee
* National AMR policy platform
* National Medicines Policy Technical Working Group, among others.
Translational Health Sciences
Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devasting consequences on treatment and prevention programmes, including for HIV and TB across the globe. Mitchell Warren will provide updates on AIDS Vaccine Advocacy Coalition's (AVAC) court challenge against the Trump administration’s dismantling of USAID and offer his insights into what a more resilient global health funding infrastructure could look like.
About the speaker:
Mitchell Warren has spent nearly 30 years devoted to expanding access to HIV prevention, working with a wide range of activists and advocates, researchers and scientists, product developers and deliverers, policy makers, community advisory boards and the media from across the globe. This has often been as a translator, helping these often-diverse groups with diverse points of view understand each other better.
Since 2004, Mitchell has been the Executive Director of AVAC, an international non-governmental organization that works to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive and integrated pathway to global health equity. Through communications, education, policy analysis, advocacy and a network of global collaborations, it mobilizes and supports efforts to deliver proven HIV prevention tools for immediate impact, demonstrates and rolls out new HIV prevention options, and develops long-term solutions needed to end the epidemic.
